These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 30784233)

  • 1. Multimodal prevention of first psychotic episode through N-acetyl-l-cysteine and integrated preventive psychological intervention in individuals clinically at high risk for psychosis: Protocol of a randomized, placebo-controlled, parallel-group trial.
    Schmidt SJ; Hurlemann R; Schultz J; Wasserthal S; Kloss C; Maier W; Meyer-Lindenberg A; Hellmich M; Muthesius-Digón A; Pantel T; Wiesner PS; Klosterkötter J; Ruhrmann S;
    Early Interv Psychiatry; 2019 Dec; 13(6):1404-1415. PubMed ID: 30784233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale and baseline characteristics of PREVENT: a second-generation intervention trial in subjects at-risk (prodromal) of developing first-episode psychosis evaluating cognitive behavior therapy, aripiprazole, and placebo for the prevention of psychosis.
    Bechdolf A; Müller H; Stützer H; Wagner M; Maier W; Lautenschlager M; Heinz A; de Millas W; Janssen B; Gaebel W; Michel TM; Schneider F; Lambert M; Naber D; Brüne M; Krüger-Özgürdal S; Wobrock T; Riedel M; Klosterkötter J;
    Schizophr Bull; 2011 Sep; 37 Suppl 2(Suppl 2):S111-21. PubMed ID: 21860040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Staged treatment and acceptability guidelines in early psychosis study (STAGES): A randomized placebo controlled trial of intensive psychosocial treatment plus or minus antipsychotic medication for first-episode psychosis with low-risk of self-harm or aggression. Study protocol and baseline characteristics of participants.
    O'Donoghue B; Francey SM; Nelson B; Ratheesh A; Allott K; Graham J; Baldwin L; Alvarez-Jimenez M; Thompson A; Fornito A; Polari A; Berk M; Macneil C; Crisp K; Pantelis C; Yuen HP; Harrigan S; McGorry P
    Early Interv Psychiatry; 2019 Aug; 13(4):953-960. PubMed ID: 30024100
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Wasserthal S; Muthesius A; Hurlemann R; Ruhrmann S; Schmidt SJ; Hellmich M; Schultze-Lutter F; Klosterkötter J; Müller H; Meyer-Lindenberg A; Poeppl TB; Walter H; Hirjak D; Koutsouleris N; Fallgatter AJ; Bechdolf A; Brockhaus-Dumke A; Mulert C; Philipsen A; Kambeitz J
    Schizophr Bull Open; 2024 Jan; 5(1):sgae005. PubMed ID: 39144108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mindfulness-based social cognition training (SocialMIND) versus psychoeducational multicomponent intervention for people with a first episode of psychosis: a study protocol for a randomised controlled trial.
    Mediavilla R; Muñoz-Sanjose A; Rodriguez-Vega B; Bayon C; Palao A; Lahera G; Sanchez-Castro P; Roman E; Cebolla S; de Diego A; Pastor JM; Bravo-Ortiz MF
    BMC Psychiatry; 2019 Jul; 19(1):233. PubMed ID: 31357965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ENACT: a protocol for a randomised placebo-controlled trial investigating the efficacy and mechanisms of action of adjunctive N-acetylcysteine for first-episode psychosis.
    Cotton SM; Berk M; Watson A; Wood S; Allott K; Bartholomeusz CF; Bortolasci CC; Walder K; O'Donoghue B; Dean OM; Chanen A; Amminger GP; McGorry PD; Burnside A; Uren J; Ratheesh A; Dodd S
    Trials; 2019 Nov; 20(1):658. PubMed ID: 31779696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can antipsychotic dose reduction lead to better functional recovery in first-episode psychosis? A randomized controlled-trial of antipsychotic dose reduction. The reduce trial: Study protocol.
    Weller A; Gleeson J; Alvarez-Jimenez M; McGorry P; Nelson B; Allott K; Bendall S; Bartholomeusz C; Koval P; Harrigan S; O'Donoghue B; Fornito A; Pantelis C; Paul Amminger G; Ratheesh A; Polari A; Wood SJ; van der El K; Ellinghaus C; Gates J; O'Connell J; Mueller M; Wunderink L; Killackey E
    Early Interv Psychiatry; 2019 Dec; 13(6):1345-1356. PubMed ID: 30488637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-acetylcysteine add-on treatment leads to an improvement of fornix white matter integrity in early psychosis: a double-blind randomized placebo-controlled trial.
    Klauser P; Xin L; Fournier M; Griffa A; Cleusix M; Jenni R; Cuenod M; Gruetter R; Hagmann P; Conus P; Baumann PS; Do KQ
    Transl Psychiatry; 2018 Oct; 8(1):220. PubMed ID: 30315150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study protocol for a randomised controlled trial of CBT vs antipsychotics vs both in 14-18-year-olds: Managing Adolescent first episode Psychosis: a feasibility study (MAPS).
    Pyle M; Broome MR; Joyce E; MacLennan G; Norrie J; Freeman D; Fowler D; Haddad PM; Shiers D; Hollis C; Smith J; Liew A; Byrne RE; French P; Peters S; Hudson J; Davies L; Emsley R; Yung A; Birchwood M; Longden E; Morrison AP
    Trials; 2019 Jul; 20(1):395. PubMed ID: 31272477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A study protocol for the N-ICE trial: A randomised double-blind placebo-controlled study of the safety and efficacy of N-acetyl-cysteine (NAC) as a pharmacotherapy for methamphetamine ("ice") dependence.
    McKetin R; Dean OM; Turner A; Kelly PJ; Quinn B; Lubman DI; Dietze P; Carter G; Higgs P; Baker AL; Sinclair B; Reid D; Manning V; Te Pas N; Liang W; Thomas T; Bathish R; Kent M; Raftery D; Arunogiri S; Cordaro F; Hill H; Berk M
    Trials; 2019 Jun; 20(1):325. PubMed ID: 31164169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: twelve-month outcome.
    McGorry PD; Nelson B; Phillips LJ; Yuen HP; Francey SM; Thampi A; Berger GE; Amminger GP; Simmons MB; Kelly D; Dip G; Thompson AD; Yung AR
    J Clin Psychiatry; 2013 Apr; 74(4):349-56. PubMed ID: 23218022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial.
    Amminger GP; Schäfer MR; Papageorgiou K; Klier CM; Cotton SM; Harrigan SM; Mackinnon A; McGorry PD; Berger GE
    Arch Gen Psychiatry; 2010 Feb; 67(2):146-54. PubMed ID: 20124114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment in early psychosis with N-acetyl-cysteine for 6months improves low-level auditory processing: Pilot study.
    Retsa C; Knebel JF; Geiser E; Ferrari C; Jenni R; Fournier M; Alameda L; Baumann PS; Clarke S; Conus P; Do KQ; Murray MM
    Schizophr Res; 2018 Jan; 191():80-86. PubMed ID: 28711476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Staged Treatment in Early Psychosis: A sequential multiple assignment randomised trial of interventions for ultra high risk of psychosis patients.
    Nelson B; Amminger GP; Yuen HP; Wallis N; J Kerr M; Dixon L; Carter C; Loewy R; Niendam TA; Shumway M; Morris S; Blasioli J; McGorry PD
    Early Interv Psychiatry; 2018 Jun; 12(3):292-306. PubMed ID: 28719151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Detection and early treatment of subjects at high risk of clinical psychosis: Definitions and recommendations].
    Michel C; Toffel E; Schmidt SJ; Eliez S; Armando M; Solida-Tozzi A; Schultze-Lutter F; Debbané M
    Encephale; 2017 May; 43(3):292-297. PubMed ID: 28347521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-blind randomized controlled trial of oxytocin nasal spray and social cognition training for young people with early psychosis.
    Cacciotti-Saija C; Langdon R; Ward PB; Hickie IB; Scott EM; Naismith SL; Moore L; Alvares GA; Redoblado Hodge MA; Guastella AJ
    Schizophr Bull; 2015 Mar; 41(2):483-93. PubMed ID: 24962607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of Psychosis: Advances in Detection, Prognosis, and Intervention.
    Fusar-Poli P; Salazar de Pablo G; Correll CU; Meyer-Lindenberg A; Millan MJ; Borgwardt S; Galderisi S; Bechdolf A; Pfennig A; Kessing LV; van Amelsvoort T; Nieman DH; Domschke K; Krebs MO; Koutsouleris N; McGuire P; Do KQ; Arango C
    JAMA Psychiatry; 2020 Jul; 77(7):755-765. PubMed ID: 32159746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NEURAPRO-E study protocol: a multicentre randomized controlled trial of omega-3 fatty acids and cognitive-behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders.
    Markulev C; McGorry PD; Nelson B; Yuen HP; Schaefer M; Yung AR; Thompson A; Berger G; Mossaheb N; Schlögelhofer M; Smesny S; de Haan L; Riecher-Rössler A; Nordentoft M; Chen EYH; Verma S; Hickie I; Amminger GP
    Early Interv Psychiatry; 2017 Oct; 11(5):418-428. PubMed ID: 26279065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreasing risk of psychosis by sulforaphane study protocol for a randomized, double-blind, placebo-controlled, clinical multi-centre trial.
    Li Z; Zhang T; Xu L; Wei Y; Tang Y; Hu Q; Liu X; Li X; Davis J; Smith R; Jin H; Wang J
    Early Interv Psychiatry; 2021 Jun; 15(3):585-594. PubMed ID: 32436318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Acceptance and Commitment Therapy in Daily Life (ACT-DL) in early psychosis: study protocol for a multi-centre randomized controlled trial.
    Reininghaus U; Klippel A; Steinhart H; Vaessen T; van Nierop M; Viechtbauer W; Batink T; Kasanova Z; van Aubel E; van Winkel R; Marcelis M; van Amelsvoort T; van der Gaag M; de Haan L; Myin-Germeys I
    Trials; 2019 Dec; 20(1):769. PubMed ID: 31878966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.